Achmea Investment Management B.V. Buys 19,094 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Achmea Investment Management B.V. grew its stake in Royalty Pharma plc (NASDAQ:RPRXGet Rating) by 3,888.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,585 shares of the biopharmaceutical company’s stock after acquiring an additional 19,094 shares during the period. Achmea Investment Management B.V.’s holdings in Royalty Pharma were worth $787,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Captrust Financial Advisors grew its holdings in shares of Royalty Pharma by 210.8% in the 2nd quarter. Captrust Financial Advisors now owns 805 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 546 shares in the last quarter. Newfound Research LLC bought a new position in shares of Royalty Pharma in the 2nd quarter valued at about $50,000. PNC Financial Services Group Inc. grew its holdings in shares of Royalty Pharma by 54.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,423 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 1,208 shares in the last quarter. Advisor Group Holdings Inc. grew its holdings in shares of Royalty Pharma by 9.4% in the 1st quarter. Advisor Group Holdings Inc. now owns 4,265 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 366 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in Royalty Pharma during the third quarter worth about $164,000. Institutional investors own 55.36% of the company’s stock.

Insider Activity

In other news, CFO Terrance P. Coyne sold 24,500 shares of Royalty Pharma stock in a transaction that occurred on Tuesday, November 8th. The shares were sold at an average price of $43.47, for a total value of $1,065,015.00. Following the completion of the sale, the chief financial officer now directly owns 940,000 shares in the company, valued at $40,861,800. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, CFO Terrance P. Coyne sold 24,500 shares of Royalty Pharma stock in a transaction that occurred on Tuesday, November 8th. The shares were sold at an average price of $43.47, for a total value of $1,065,015.00. Following the completion of the sale, the chief financial officer now directly owns 940,000 shares in the company, valued at $40,861,800. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Mario Germano Giuliani sold 165,000 shares of the business’s stock in a transaction that occurred on Thursday, December 1st. The shares were sold at an average price of $44.10, for a total transaction of $7,276,500.00. Following the transaction, the director now owns 22,225,000 shares of the company’s stock, valued at $980,122,500. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 532,933 shares of company stock worth $23,027,408. Corporate insiders own 24.86% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on RPRX shares. JPMorgan Chase & Co. lifted their price target on Royalty Pharma from $50.00 to $52.00 and gave the stock an “overweight” rating in a report on Tuesday, October 18th. StockNews.com started coverage on Royalty Pharma in a report on Wednesday, October 12th. They set a “hold” rating for the company. Finally, Morgan Stanley reduced their price target on Royalty Pharma from $54.00 to $51.00 and set an “overweight” rating for the company in a report on Tuesday, December 6th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Royalty Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.71.

Royalty Pharma Trading Down 1.4 %

Shares of RPRX stock opened at $38.09 on Monday. The firm has a 50 day moving average price of $41.58 and a two-hundred day moving average price of $42.11. The company has a quick ratio of 2.07, a current ratio of 2.07 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $23.13 billion, a PE ratio of 45.35, a price-to-earnings-growth ratio of 0.86 and a beta of 0.41. Royalty Pharma plc has a 12-month low of $36.15 and a 12-month high of $44.75.

Royalty Pharma (NASDAQ:RPRXGet Rating) last issued its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.02. Royalty Pharma had a net margin of 22.61% and a return on equity of 17.26%. The firm had revenue of $597.00 million during the quarter, compared to the consensus estimate of $578.03 million. As a group, analysts predict that Royalty Pharma plc will post 3.27 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 15th. Stockholders of record on Friday, November 18th were given a $0.19 dividend. The ex-dividend date was Thursday, November 17th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 2.00%. Royalty Pharma’s payout ratio is 90.48%.

Royalty Pharma Company Profile

(Get Rating)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

See Also

Institutional Ownership by Quarter for Royalty Pharma (NASDAQ:RPRX)

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.